CASTLE BIOSCIENCES INC CEO Derek J. Maetzold exercised Options for 8,584 shares at $2.39 per share, lifting his reported share holding to 30,063. Investors also have a direct-ownership reference after 14,518 shares were sold, with 12,268 shares remaining, while derivative securities stood at 16,745.
Key Highlights
- Maetzold sold 14,518 CASTLE BIOSCIENCES INC shares at prices from $32 to $32.78 per share.
- The exercised options represented about 33.9% of his prior derivative-securities holding.
- His reported holding after the sales was 12,268 shares.
CASTLE BIOSCIENCES INC (NASDAQ: CSTL) Chief Executive Officer Derek J. Maetzold exercised options for 8,584 shares at $2.39 per share on 11 September 2026. His reported share ownership after the exercise was 30,063 shares, and the transaction represented about 28.6% of that resulting holding.
Maetzold Reports Option Exercise and Share Sales
Maetzold also sold 14,518 CASTLE BIOSCIENCES INC shares at prices ranging from $32 to $32.78 per share on 11 September 2026. The transaction code M identifies the option exercise, while code S identifies the stock sales. The exercised options represented about 33.9% of Maetzold’s prior derivative-securities holding.
Direct Shares and Derivative Securities Reported Separately
The filing reports share balances and derivative-securities balances separately. Maetzold owned 12,268 shares after the sales and 16,745 derivative securities after the option exercise. The filing reports these balances as shares and derivative securities.
FAQs
Q: How many Castle Biosciences options did Derek Maetzold exercise?
A: Derek Maetzold exercised options for 8,584 Castle Biosciences shares. The filing reports an exercise price of $2.39 per share on 11 September 2026.
Q: How many Castle Biosciences shares did Maetzold hold after the sales?
A: Maetzold held 12,268 Castle Biosciences shares after selling 14,518 shares. The sales were priced from $32 to $32.78 per share.
Q: What happened to Maetzold’s derivative securities after the option exercise?
A: Maetzold owned 16,745 derivative securities after the exercise. The exercised options represented about 33.9% of his prior derivative-securities holding, as reported in the filing.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.